ERBB2 and non-small cell lung carcinoma: More than 20 drugs have been approved by the Food and Drug Administration (FDA) as treatments for NSCLC, including 14 targeted and immunotherapeutic drugs, such as the anti-EGFR antibody, cetuximab, the EGFR and HER2 inhibitors, afatinib, the PD-L1 inhibitor, atezolizumab, and the vascular endothelial growth factor antibody, bevacizumab.